Oruka Therapeutics (ORKA) Enterprise Value (2010 - 2026)

Oruka Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$384.7 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 39.35% year-over-year to -$384.7 million; the TTM figure through Mar 2026 stood at -$384.7 million (up 39.35% YoY), while the FY2025 annual figure was -$767.5 million, down 104.32% from the prior year.
• Enterprise Value was -$384.7 million for Q1 2026 at Oruka Therapeutics, up from -$767.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$33.3 million in Q2 2024 to a low of -$767.5 million in Q4 2025.
• Historically, Enterprise Value has averaged -$214.6 million across 5 years, with a median of -$46.4 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value sank 1666.86% in 2025, then jumped 39.35% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$42.4 million in 2022, then climbed by 11.81% to -$37.4 million in 2023, then tumbled by 903.57% to -$375.6 million in 2024, then tumbled by 104.32% to -$767.5 million in 2025, then surged by 49.87% to -$384.7 million in 2026.
• The last three Enterprise Value figures came in at -$384.7 million (Q1 2026), -$767.5 million (Q4 2025), and -$346.9 million (Q3 2025), per Business Quant data.